Brief: Belite Bio Presented Interim Results Of LBSs-008 Phase 1B/2 Study In Adolescent STGD1 At Arvo Annual Meeting 2022
05/05/2022 13:23
May 5 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO PRESENTED INTERIM RESULTS OF LBS-008 PHASE 1B/2
STUDY
IN ADOLESCENT STGD1 AT ARVO ANNUAL MEETING 2022
* BELITE BIO INC - LBS-008 (AKA TINLAREBANT) SHOWED AN
ACCEPTABLE
SAFETY PROFILE IN ADOLESCENT STARGARDT DISEASE (STGD1) SUBJECTS
* BELITE BIO INC - TREND FOR STABILIZED OR IMPROVED VISUAL
ACUITY
WAS OBSERVED
* BELITE BIO INC - OBSERVED ADVERSE EVENTS WERE ANTICIPATED
BASED
ON MECHANISM OF LBS-008 ACTION
* BELITE BIO INC - STGD1 SUBJECTS FROM PHASE 1B STUDY ARE
NOW
PARTICIPATING IN 2-YEAR, PHASE 2 EXTENSION
Source text for Eikon: ID:nGNX55msGL
Further company coverage: BLTE.O
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses